#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Von Hippel-Lindau disease Cutaneous lupus erythematosus Breast cancer metastatic Thalassaemia Cutaneous T-cell lymphoma MELAS syndrome Anti-myelin-associated glycoprotein antibodies positive Phenylketonuria Biliary cancer metastatic Marginal zone lymphoma recurrent Pulmonary arterial hypertension Oesophageal adenocarcinoma stage II Fungal infection Graft versus host disease Renal disorder More trials…

    Learn about Rare Diseases

    Pemphigus – Treatment Urea cycle disorder Chronic granulomatous disease – Trials in Disease Factor IX deficiency Crigler-Najjar syndrome – Trials in Disease Haemophagocytic lymphohistiocytosis – Life with Disease Retinoblastoma – Life with Disease Usher’s syndrome Ewing’s sarcoma recurrent – Basic Information Haemophilia – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ZILUCOPLAN Fluoxetine Hydrochloride Esketamine Hydrochloride Abc-15Bo-116 STREPTOCOCCUS PYOGENES GSKVX000000044501 Sodium Cromoglicate Human Coagulation Factor X Perindopril Arginine Gskvx000000017033 Dsimc Pyrimethamine Dexamfetamine Sulfate Mifepristone DROSPIRENONE Finasteride GRISNILIMAB SETARITOX Cefoxitin Sodium ANGIOTENSIN II Prednisolone Sodium Phosphate More therapies…

    Learn about Your Condition

    Otitis media Essential hypertension Mitochondrial DNA depletion Lung neoplasm malignant Ataxia telangiectasia Intracranial aneurysm Fibromyalgia Glioma Thalassaemia beta MELAS syndrome Pharyngeal cancer stage III Tuberculosis Psoriasis Deep vein thrombosis Meniscus operation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Study on Immune Markers for Checkpoint Inhibitor Toxicity in Cancer Patients Using Atezolizumab, Dexamethasone Sodium Phosphate, and Alizapride

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Alizapride
    • Cetirizine
    • Pegfilgrastim
    Belgium

  • Study on Early Treatment of Persistent Atrial Fibrillation: Comparing Cryoballoon Therapy with Dronedarone, Flecainide, Sotalol, and Propafenone in Symptomatic Patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Dronedarone
    • Sotalol
    Bulgaria Denmark Germany Hungary Norway Slovakia +1

  • Study on Long-Term Safety of Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease

    Recruiting

    3 1 1
    Investigated Drugs:
    • Fazirsiran
    Austria Germany Portugal

  • Study on the Safety and Tolerability of Lixudebart and Rituximab for Patients with Rapidly Progressive Glomerulonephritis Due to ANCA-Associated Vasculitis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Glomerulonephritis rapidly progressive
    Investigated Drugs:
    • Lixudebart
    • Rituximab
    Czechia Denmark France Germany Italy Spain +1

  • Study on TAK-330 for Reversing Anticoagulation in Patients on Factor Xa Inhibitors Needing Urgent Surgery

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Thrombosis prophylaxis
    Investigated Drugs:
    • Human Coagulation Factor Ii
    • Human Coagulation Factor Ix
    • Human Coagulation Factor Vii
    Austria Belgium Czechia France Germany Greece +5

  • Study on the Safety and Effects of Luspatercept for Children with Beta Thalassemia

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Thalassaemia beta
    Investigated Drugs:
    • Luspatercept
    Germany Greece Italy
Previous Page
1 … 593 594 595 596 597 … 1,655
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!